Novartis

News

Novartis on track to bring first CAR-T to market

Novartis says its chimeric antigen receptors (CAR-T) candidate is on track for filing in 2017, which could make it the first of the novel drugs to hit the market.

News

Novartis drug gets 'Promising Innovative Medicine' status in...

Novartis's cancer drug Zykadia has become one of the first drugs to snag Promising Innovation Medicine status in the UK's new early access scheme.

News

New dermatology licence for Xolair

Xolair has gained EU approval as the first ever add-on therapy to treat chronic spontaneous urticaria (CSU) in adult and adolescent patients with inadequate response to H1-antihistamine tre

Articles

A history of Novartis

Novartis is one of the world's top pharmaceutical companies, and along with neighbours Roche, the mainstay of Switzerland's centuries-long contribution to new medicines.

News

Novartis’ acute gouty arthritis drug approved in Europe

Novartis has received European Commission approval for its acute gouty arthritis medicine

Novartis on track to bring first CAR-T to market

Novartis drug gets 'Promising Innovative Medicine' status in...

New dermatology licence for Xolair

A history of Novartis

Novartis’ acute gouty arthritis drug approved in Europe

BridgeBio gains on phase 3 dwarfism data

How to meet your physicians where they are online

Novartis

Editor's Picks